SeekingAlpha  Jun 20  Comment 
By Stephen Simpson, CFA: Danish specialty pharmaceutical company H Lundbeck A/S (OTCPK:HLUYY) (LUN.CO) is facing down some steep patent cliffs, as about two-thirds of the company's first revenue loses patent protection over the next two and a half...
StreetInsider.com  Jun 19  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Chelsea+Therapeutics+%28CHTP%29+Reports+Publication+of+Statistically+Significant+NORTHERA+Phase+3+Data/9599220.html for the full story.
StreetInsider.com  Jun 12  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Chelsea+Therapeutics+%28CHTP%29+Presents+Significant+Date+from+Two+Pivotal+NORTHERA+Studies/9576800.html for the full story.
StreetInsider.com  Jun 6  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Chelsea+Therapeutics+%28CHTP%29+Reports+Expiration+of+HSR+Act+in+Lundbeck+Deal/9560700.html for the full story.
SeekingAlpha  Jun 2  Comment 
By shareholder_boar: On May 7, 2014, Chelsea Therapeutics (CHTP) agree to be acquired by the Danish corporation H. Lundbeck A/S (OTCPK:HLUYY). The acquisition is structured as a tender offer followed by a second step merger. The tender offer has...
SeekingAlpha  May 29  Comment 
By New Capital: Investment thesis Investment in Chelsea Therapeutics (CHTP) presents a very asymmetric risk/return opportunity. On 7th of May, the company announced a merger agreement and going private transaction with Lundbeck (OTCPK:HLUYY)....
DailyFinance  May 21  Comment 
Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of Chelsea Therapeutics...
Benzinga  May 9  Comment 
JMP & Needham suggest that Chelsea Therapeutics International Ltd. (NASDAQ: CHTP) is not likely to see other offers following the Lundneck bid. JMP analyst Jason Butler called Chelsea Therapeutics sale process “thorough” and sees a...
DailyFinance  May 9  Comment 
Newman Ferrara LLP is investigating potential claims against the board of directors of Chelsea Therapeutics International (“Chelsea”) (Nasdaq: CHTP) concerning the proposed sale of Chelsea to Danish corporation H. Lundbeck...
Benzinga  May 8  Comment 
Chelsea Therapeutics International (NASDAQ: CHTP) climbed 30.02% to $6.50 after Lundbeck announced its plans to acquire Chelsea Therapeutics for up to $658 million. Numerex (NASDAQ: NMRX) gained 18.26% to $11.97 after the company reported...



Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki